1. Economic Evaluation of anti-epileptic Medicines for Autistic Children with Epilepsy.
- Author
-
Tinelli M M, Roddy A, Knapp M, Arango C, Mendez MA, Cusack J, Murphy D, Canitano R, Oakley B, and Quoidbach V
- Subjects
- Humans, Child, Carbamazepine therapeutic use, Carbamazepine economics, Spain, Ireland, Italy, Gabapentin therapeutic use, Oxcarbazepine therapeutic use, England, Male, gamma-Aminobutyric Acid therapeutic use, gamma-Aminobutyric Acid economics, gamma-Aminobutyric Acid analogs & derivatives, Female, Amines therapeutic use, Amines economics, Anticonvulsants therapeutic use, Anticonvulsants economics, Epilepsy drug therapy, Epilepsy economics, Cost-Benefit Analysis, Autistic Disorder drug therapy, Autistic Disorder economics
- Abstract
We examine the cost-effectiveness of treating epilepsy with anti-epileptic medicines in autistic children, looking at impacts on healthcare providers (in England, Ireland, Italy and Spain) and children's families (in Ireland). We find carbamazepine to be the most cost-effective drug to try first in children with newly diagnosed focal seizures. For England and Spain, oxcarbazepine is the most cost-effective treatment when taken as additional treatment for those children whose response to monotherapy is suboptimal. In Ireland and Italy, gabapentin is the most cost-effective option. Our additional scenario analysis presents the aggregate cost to families with autistic children who are being treated for epilepsy: this cost is considerably higher than healthcare provider expenditure., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF